Article PDF
References
Hardy JF, Belisle S, Janvier G, Samama M. Reduction in requirements for allogeneic blood products: non-pharmacologic methods. Ann Thorac Surg 1996; 62: 1935–43.
Janssens M, Hartstein G, David JL. Reduction in requirements for allogeneic blood products: pharmacologic methods. Ann Thorac Surg 1996; 62: 1944–50.
Lemmer JH Jr. Reporting the results of blood conservation studies: the need for uniform and comprehensive methods (Editorial). Ann Thorac Surg 1994; 58: 1305–6.
Goodnough LT, Johnston MFM, Toy PTCY, and the Transfusion Medicine Academic Award Group. The variability of transfusion practice in coronary artery bypass surgery. JAMA 1991; 265: 86–90.
Fremes SE, Wong BI, Lee E, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58: 1580–8.
Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physicians’ transfusion practice in cardiac surgery. Transfusion 1994; 34: 290–6.
Ferraris VA, Ferraris SP. Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Tex Heart Inst J 1995; 22: 216–30.
Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996; 62: 1908–17.
Lu H, Du Buit C, Soria J, et al. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy. Thromb Haemost 1994; 72: 438–43.
Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5: 467–74.
Blauhut B, Gross C, Necek S, Doran JE, Späth P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss,platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958–67.
Øvrum E, Am Holen E, Abdelnoor M, Øystese R, Ringdal ML. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg 1993; 105: 78–83.
Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994; 80: 520–6.
Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen (Editorial). Ann Thorac Surg 1996; 62: 1575–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hardy, JF., Bélisle, S. Natural and synthetic antifibrinolytics: Inert, poisonous or therapeutic agents?. Can J Anaesth 44, 913–917 (1997). https://doi.org/10.1007/BF03011960
Issue Date:
DOI: https://doi.org/10.1007/BF03011960